Canada: I Want A New Drug: Developments In Data Protection For Innovative Drugs

In the highly competitive market for pharmaceuticals, the market exclusivity provided to the manufacturers of innovative drugs by the data protection regime of the Food and Drug Regulations (the Regulations) is important, and has the potential to be extremely lucrative. Two recent federal court decisions highlight some of the ambiguities in the Regulations and provide guidance on how courts interpret the Regulations.

Overview of Data Protection Regime in Canada

In order for a new drug to be sold in Canada, it must be approved by the Minister of Health (the Minister) in the form of a Notice of Compliance (NOC). The approval process is different for brand name drugs, many of which are also "innovative drugs", as compared to their generic counterparts. An "innovative drug" is defined in the Regulations as "a drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph." (emphasis added)

In Canada, manufacturers of innovative drugs are required to file a New Drug Submission (NDS) with the Minister, containing safety and efficacy information. The Minister issues an NOC only after determining that the benefits of the drug outweigh the risks, and that the risks can be mitigated and/or managed. Generic manufacturers, on the other hand, generally obtain drug approval by filing an Abbreviated New Drug Submission (ANDS), which is intended to establish bioequivalence with an existing "reference product", usually a previously approved innovative drug. Instead of providing clinical data to demonstrate safety and efficacy, generic manufacturers rely on the data provided by the innovator at the time the innovative drug was approved.

In this context, and in keeping with its international treaty obligations, Canada provides protection to the safety and efficacy data submitted by the innovator. Specifically, the Regulations prohibit the Minister from issuing an NOC to a manufacturer that makes a direct or indirect comparison to an innovative drug until at least eight years have passed from the issuance of the NOC for the innovative drug at issue. The eight-year period of protection may be extended by six months if, within the first five years of the protection period, the results of pediatric clinical trials designed and conducted for the purpose of increasing knowledge of the use of the drug in pediatric populations, are submitted and found acceptable.

The Regulations also provide for a "no filing" period, whereby the generic manufacturer is prohibited from filing its ANDS for the first six years of the eight-year data protection period. The Minister maintains a Register of Innovative Drugs (the Register) to track the dates on which the six-year, eight-year and, where applicable, pediatric extension periods, will expire.

No Special Access to Data Protection

In Teva Canada Limited v. Canada (Health), the Federal Court of Appeal (FCA) confirmed that drugs made available pursuant to Health Canada's Special Access Programme (the SAP) are not considered "previously approved" under the Regulations and are therefore eligible for data protection.

Teva Canada wanted to market a generic version of ELOXATIN but was being prevented from doing so because it was listed on the Register and therefore benefited from the data protection provisions of the Regulations. In 2010, Teva Canada requested that the Minister remove ELOXATIN from the Register on the basis that it did not meet the definition of "innovative drug" under the Regulations. Teva Canada argued that because ELOXATIN had been available under the SAP (a program designed to provide exceptional access to unapproved drugs on a compassionate or emergency basis to patients with serious or life-threatening conditions) since 1999, it has been "previously approved" by the Minister. The Minister rejected Teva Canada's request and an appeal to the Federal Court of Canada (FCC) was dismissed. Teva Canada made a further appeal to the FCA.

In denying Teva Canada's appeal, the FCA considered the issue of whether authorizations under the SAP could make a drug "previously approved" for the purposes of the data protection provisions of the Regulations. The court in this case focused on the primary purpose of the Regulations themselves and found that they are directed to the safety and efficacy of drugs. Specifically, the court noted that a drug is only "approved" by the Minister when it has been found to be safe and effective. The Minister does not determine the safety and effectiveness of a drug under the SAP. Accordingly, drugs under the SAP are not "approved" by the Minister.

Furthermore, the court noted that the data protection regime under the Regulations was designed to implement specific treaty obligations. Those treaty provisions repeatedly refer to the concept of market approval. Since, in Canada, marketing approval requires the issuance of an NOC, sale under the SAP did not mean market approval. To find otherwise might put Canada offside its treaty obligations.

New Uses for Old Drugs

In Celgene Inc. v. The Minister of Health, the FCC considered what data protection, if any, was available to a drug whose medicinal ingredient had previously been approved for sale in Canada. The medicinal ingredient at issue, thalidomide, was approved for sale in Canada in 1960 and was used to treat sleeplessness, minor ailments, and morning sickness in pregnant women. By 1962, data linking thalidomide with serious birth defects and deaths prompted Health Canada to order its permanent withdrawal from the market.

Despite its history, further research found that thalidomide was effective in treating various conditions, including leprosy and cancer. Celgene began offering thalidomide in association with the trade-mark THALOMID and in 1995 it was made available in Canada through the SAP.

In 2009, Celgene sought approval to sell THALOMID in Canada outside of the SAP and an NOC was issued in 2010. However, when the NOC was issued, the Minister advised Celgene that because thalidomide had been previously approved by the Minister, THALOMID was not eligible for data protection. Celgene appealed that ruling to the FCC.

The court was tasked with interpreting the meaning of "innovative drug" and determining whether the Minister's prior approval of thalidomide constituted an approval within the meaning of "approved" in the definition of "innovative drug". The Minister took the position that the intent of the data protection provisions of the Regulations is to reserve the special market exclusivity period for genuinely new and innovative medicinal ingredients. According to the Minister, new uses of ingredients that had been previously approved for a different use should not qualify for data protection.

The FCC did not accept the Minister's position and held that THALOMID was eligible for data protection. A key aspect of the court's decision was its finding that the purpose and intent of the Regulations is to encourage innovation and the development of drugs that can be used by Canadians. In that context, the court concluded that Celgene's innovation was to take something that had been banned as dangerous and show it to be a useful, potentially lifesaving drug. In doing so, Celgene could not rely on data from the prior approval for thalidomide and had to produce entirely new data. The court held that it would be inconsistent with Canada's international treaty obligations to refuse data protection when a medicinal ingredient is put to an entirely new use based on extensive and genuinely new data demonstrating its safety and efficacy.

On that basis, the court concluded that the Minister's decision was incorrect and that thalidomide qualified as a medicinal ingredient not previously approved. It was therefore eligible for listing on the Register.

Due to the exceptional circumstances surrounding the use of thalidomide in Canada, the future impact of the Celgene decision may be limited. However, the case provides a useful example of the types of legal considerations that may arise in a research environment where old drugs essentially become new again. Indeed, one of the growing trends in pharmaceutical research is to identify new therapeutic uses for existing compounds that are not currently being marketed.

For example, in May 2012, the National Institutes of Health in the U.S. launched a pilot program called Discovering New Therapeutic Uses for Existing Molecules. The program matches biomedical researchers with a selection of compounds that have been developed by industry and that have already undergone significant testing, including safety testing in humans. Successful applicants will have the opportunity to work with the compounds (deemed unsuitable for their intended therapeutic indication or not pursued for business reasons) to see if they can develop new treatments or therapies. To date, eight major pharmaceutical companies are participating in the program and 58 compounds have been made available for further study. Grants are expected to be awarded by summer 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Oct 2016, Seminar, Toronto, Canada

Please join members of the Blakes Commercial Real Estate group as they discuss five key provisions of a commercial real estate purchase agreement that are often the subject of much negotiation but are sometimes misunderstood.

1 Nov 2016, Seminar, Toronto, Canada

What is the emotional culture of your organization?

Every organization and workplace has an emotional culture that can have an impact on everything from employee performance to customer or client satisfaction.

3 Nov 2016, Seminar, Toronto, Canada

Join leading lawyers from the Blakes Pensions, Benefits & Executive Compensation group as they discuss recent updates and legal developments in pension and employee benefits law as well as strategies to identify and minimize common risks.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.